Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$2.90
-1.0%
$3.33
$1.72
$3.84
$27.26M1.4925,704 shs3,826 shs
Ceapro Inc. stock logo
CZO
Ceapro
C$0.26
+8.3%
C$0.23
C$0.15
C$0.64
C$20.36M1.3950,465 shs72,000 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$1.50
+1.4%
$1.62
$1.46
$3.82
$25.19M0.8784,659 shs38,503 shs
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-0.39%-4.30%-13.87%+14.84%+8.37%
Ceapro Inc. stock logo
CZO
Ceapro
0.00%-4.00%0.00%+50.00%-57.89%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
+0.68%-1.99%-8.64%-12.94%-28.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
2.2892 of 5 stars
3.53.00.00.01.70.81.3
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.269 of 5 stars
3.54.00.04.72.50.80.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.00106.90% Upside
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
3.00
Buy$6.00300.00% Upside

Current Analyst Ratings

Latest UBX, ACST, CZO, C4XD, and HBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$10.00 ➝ $8.00
2/7/2024
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
Ceapro Inc. stock logo
CZO
Ceapro
C$11.30M1.80C$0.07 per share3.94C$0.38 per share0.68
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
$240K104.94N/AN/A$1.69 per share0.89

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
Ceapro Inc. stock logo
CZO
Ceapro
-C$2.81M-C$0.03N/AN/A-24.86%-9.09%-6.91%5/23/2024 (Estimated)
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
-$39.86M-$2.94N/AN/AN/AN/A-95.06%-46.86%5/14/2024 (Estimated)

Latest UBX, ACST, CZO, C4XD, and HBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/15/2024Q4 2023
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/A-$0.53-$0.53-$0.78N/AN/A
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
Ceapro Inc. stock logo
CZO
Ceapro
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
Ceapro Inc. stock logo
CZO
Ceapro
7.82
11.00
18.88
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
N/A
5.94
5.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
Ceapro Inc. stock logo
CZO
Ceapro
N/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
54.10%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
29.49%

Insider Ownership

CompanyInsider Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
13.51%
Ceapro Inc. stock logo
CZO
Ceapro
4.01%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
10.95%
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
4.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
Ceapro Inc. stock logo
CZO
Ceapro
N/A78.29 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
Unity Biotechnology, Inc. stock logo
UBX
Unity Biotechnology
2216.79 million15.96 millionOptionable

UBX, ACST, CZO, C4XD, and HBP Headlines

SourceHeadline
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual MeetingUNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting
globenewswire.com - April 25 at 8:00 AM
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DMEUNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME
globenewswire.com - April 23 at 8:00 AM
Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.s FY2024 Earnings (NASDAQ:UBX)Equities Analysts Issue Forecasts for Unity Biotechnology, Inc.'s FY2024 Earnings (NASDAQ:UBX)
americanbankingnews.com - April 19 at 2:31 AM
Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)Q1 2024 Earnings Forecast for Unity Biotechnology, Inc. Issued By HC Wainwright (NASDAQ:UBX)
americanbankingnews.com - April 18 at 1:26 AM
YOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUBYOUTH UNITY EVENT TO BE HELD AT BOYS AND GIRLS CLUB
kscj.com - April 17 at 7:01 PM
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC WainwrightUnity Biotechnology (NASDAQ:UBX) Price Target Cut to $8.00 by Analysts at HC Wainwright
americanbankingnews.com - April 17 at 3:42 AM
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023
investorplace.com - April 15 at 12:06 PM
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
globenewswire.com - April 15 at 7:00 AM
Unity Biotechnology, Inc. (0YC0.L)Unity Biotechnology, Inc. (0YC0.L)
finance.yahoo.com - April 9 at 7:15 PM
UBX Mar 2024 2.000 callUBX Mar 2024 2.000 call
finance.yahoo.com - February 17 at 6:28 AM
Unity Biotechnology Inc (UBX)Unity Biotechnology Inc (UBX)
uk.investing.com - February 7 at 9:59 AM
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision LossNew Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss
finance.yahoo.com - February 6 at 10:46 AM
Guest column: UNITY is making strides in tackling homelessness in Tremes despite what critics sayGuest column: UNITY is making strides in tackling homelessness in Tremes despite what critics say
nola.com - February 1 at 6:40 PM
10 Supplements for Longevity and Antiaging: Expert Recommendations10 Supplements for Longevity and Antiaging: Expert Recommendations
finance.yahoo.com - December 29 at 6:53 PM
UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325UNITY Biotechnology doses first patients in phase 2 ASPIRE study of UBX1325
pharmabiz.com - December 14 at 2:33 AM
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DMEUNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME
finance.yahoo.com - December 12 at 8:12 AM
Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63Unity Biotechnology (UBX) Price Target Increased by 8.33% to 6.63
msn.com - November 27 at 7:50 AM
Wedbush Upgrades Unity Biotechnology (UBX)Wedbush Upgrades Unity Biotechnology (UBX)
msn.com - November 17 at 6:09 AM
Wedbush upgrades Unity Biotechnology to outperform, cites cash runwayWedbush upgrades Unity Biotechnology to outperform, cites cash runway
msn.com - November 16 at 4:06 PM
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite RiskyCompanies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
finance.yahoo.com - November 16 at 11:05 AM
Unity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy RatingUnity Biotechnology’s Promising Senolytic Therapy UBX1325 and Financial Stability Bolsters Buy Rating
markets.businessinsider.com - November 15 at 11:51 AM
Unity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUnity Biotechnology, Inc.: UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
finanznachrichten.de - November 14 at 10:45 PM
Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16
msn.com - November 14 at 2:01 AM
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business UpdatesUNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates
tmcnet.com - November 13 at 9:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Ceapro logo

Ceapro

CVE:CZO
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
Huttig Building Products logo

Huttig Building Products

NASDAQ:HBP
Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.
Unity Biotechnology logo

Unity Biotechnology

NASDAQ:UBX
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.